Ghevaert Cedric headshot

Dr Cédric Ghevaert


Laboratory Location:

Cambridge Blood Centre, NHS Blood and Transplant, Cambridge Biomedical Campus

Departmental Affiliation:

Department of Haematology


Cedric Ghevaert is a Principal Investigator at the Wellcome Trust - Medical Research Council Stem Cell Institute and is also a Senior Lecturer in Transfusion Medicine at the University of Cambridge and Consultant Haematologist for NHS Blood and Transplant.

Ghevaert research image 2-1ratio
Megakaryocytes were produced from human pluripotent stem cells through over expression of 3 key transcription factors TAL1, GATA1 and FLI1. These cells are capable of producing platelets that contain the granules (in red) necessary to perform their clotting function after transfusion. Green= alpha-tubulin, Red=P-selectin, Blue=nuclei.


The main focus of my group’s research is the production of blood cells for human use, namely red cells and platelets. We have developed a particular expertise in the production of these cell types from human pluripotent stem cells using methodologies that are compatible with the production of clinical grade products within the constraints of affordable manufacturing processes. To this end we are combining cellular programming through knowledge and manipulation of transcription fa ctor networks and the creation of 3D biocompatible niches and bioreactors.

As a consultant haematologist for the NHS Blood and Transplant (a partner organisation of the University of Cambridge) I have an expertise recognised world-wide in carrying out first-in-man studies of blood cell survival and recovery in human volunteers. I am the clinical lead for 3 such trials due to take place in the next 5 years on the Cambridge Biomedical Campus.

Ghevaert group 2-1ratio

Cavan Bennett

 Daniel Howard

Guenaelle Bouet

 Julie May

Amanda Dalby

 Thomas Moreau

Holly Foster

 Annett Müller

Nina Herbert

 Amie Waller

Plain English

We are currently entirely reliant on blood donors for the red cells and platelets transfusion we administer to patients who are very anaemic or at high risk of bleeding. Producing these blood cells in the laboratory would take the pressure of the supply chain and would make finding compatible blood for patients with rare blood groups easier. We are developing novel methods to produce red cells and platelets from human stem cells by using key “identity switches” and programming the stem cells to become blood cells. This method generates highly pure cell harvest with large quantities of blood cells to the point that we are now setting up clinical trials to assess these cells in human volunteers.

Key Publications

Web design by Studio 24 / Back to top